ArticleDrugs in context2026
Lack of association between rheumatoid factor levels and clinical response to certolizumab pegol in patients with rheumatoid arthritis: an observational study.
Article in Drugs in context, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Patients with rheumatoid arthritis (RA) generally have elevated levels of rheumatoid factor (RF), which binds to the crystallizable fraction (Fc) of monoclonal antibodies, diminishing tumour necrosis factor inhibitor (TNFi) efficacy. We assessed clinical response to PEGylated, Fc-free certolizumab pegol (CZP) across baseline RF levels in Brazilian patients with RA. Methods: Reported patients (>6 months disease duration) received CZP (200 mg every 2 weeks [Q2W] or 400 mg Q4W) after failure or intolerance to conventional synthetic or biologic disease-modifying antirheumatic drugs. Data were collected from medical records before initiation, at 3 months and at 6 months of CZP. Patients were stratified by baseline RF quartiles. Disease activity was assessed by the Clinical Disease Activity Index (CDAI). Results: Amongst 51 patients, 49 (96.1%) were women, the mean age (standard deviation [SD]) was 49.8 (13.7) years and 23 (45.1%) were receiving methotrexate. RA duration (SD) was 17.0 (9.5) years. Of 43 patients with baseline RF values, mean RF (SD) was 224.3 (363.5) IU/mL. At baseline, 3 months and 6 months, CDAI for patients overall was 18.6 (10.4), 9.8 (8.6) and 12.5 (11.7); for those with baseline RF≤Q3 ( Conclusion: Baseline RF values did not appear to influence CZP clinical response in this cohort of patients with RA. However, small sample size and data heterogeneity restricted generalizability. Efficacy data from larger cohorts may further elucidate the impact of high RF levels in patients receiving Fc-free biologics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.